The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease

Boehringer Ingelheim

Status: Completed

Conditions: Parkinson Disease

Treatments: Drug: Sifrol®

Study type: Observational

Funder types: Industry

Identifiers

NCT02231294

248.511

Details and patient eligibility

About

Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions

Enrollment: 1,464 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with idiopathic Parkinson's disease with tremor and/or depression requiring therapy with Sifrol® or change of therapy to Sifro®l and not under medication with neuroleptics were allowed to be observed during the study

Exclusion criteria

• Patients who meet one or more of the general or specific contraindications mentioned in the Summary of Product Characteristics (SPC) for Sifrol®
• Patients under treatment with neuroleptics should not be observed during this study

Trial design

1,464 participants in 1 patient group

Idiopathic Parkinson's Disease Patients

Treatment:

Drug: Sifrol®